ERBB2 and triple-negative breast carcinoma: In the presence of cT > 2 cm and/or N+, NAT was administered to 44.2% of HER2+/HR+ patients, 69.1% of HER2+/HR-negative patients, in 17.2% of HER2-negative/HR+ and 49.1% of triple negative breast cancer patients (p < 0.0001).